Option Care Health (OPCH)
(Delayed Data from NSDQ)
$31.45 USD
-0.34 (-1.07%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $31.46 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.45 USD
-0.34 (-1.07%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $31.46 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OPCH vs. ASTH: Which Stock Is the Better Value Option?
by Zacks Equity Research
OPCH vs. ASTH: Which Stock Is the Better Value Option?
Wall Street Analysts Predict a 31.8% Upside in Option Care (OPCH): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.8% in Option Care (OPCH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should Value Investors Buy Option Care Health (OPCH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Option Care (OPCH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 7.14% and 4.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -1.26% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include J.Jill, Option Care Health and Amphenol
by Zacks Equity Research
J.Jill, Option Care Health and Amphenol have been highlighted in this Screen of The Week article.
3 Stocks Backed by High Efficiency to Boost Portfolio Returns
by Santanu Roy
Invest in stocks of J.Jill (JILL), Option Care Health (OPCH) and Amphenol (APH) to tap their high-efficiency levels.
New Strong Buy Stocks for June 10th
by Zacks Equity Research
NEM, ODP, IMMR, WSM and OPCH have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2024.
Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon
by Moumi Mondal
Investing in beaten-down stocks like OPCH, LNTH and HOLX can be profitable for investors in the long term.
Option Care (OPCH) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Option Care (OPCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
by Shaun Pruitt
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.
Zacks.com featured highlights include Option Care Health, Merchants, Teekay Tankers and GigaCloud
by Zacks Equity Research
Option Care Health, Merchants, Teekay Tankers and GigaCloud have been highlighted in this Screen of The Week article.
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
3 Stocks Backed by High Efficiency to Strengthen Your Portfolio
by Santanu Roy
Invest in companies like Option Care Health (OPCH), ReWalk Robotics Ltd. (LFWD) and Garmin (GRMN), as they boast higher efficiency levels.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
4 Must-Buy Profitable Stocks Using Net Income Ratio
by Tirthankar Chakraborty
Option Care Health (OPCH), Merchants Bancorp (MBIN), Teekay Tankers (TNK), and GigaCloud Technology (GCT) have been selected as the top picks with a high net income ratio.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Option Care (OPCH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Option Care (OPCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Investors Undervaluing Option Care Health (OPCH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 4.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Option Care (OPCH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Option Care (OPCH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Option Care (OPCH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Option Care (OPCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Option Care (OPCH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 10.34% and 2.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?